Ts-Ting Lin

Affiliations: 
2013-2015 Biomedical University National Tsing Hua University, Hsinchu City, Taiwan, ROC 
Google:
"Ts-Ting Lin"
BETA: Related publications

Publications

You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect.

Juang JJ, Liu YB, Chen CJ, et al. (2020) Validation and Disease Risk Assessment of Previously Reported Genome-Wide Genetic Variants Associated with Brugada Syndrome: SADS-TW BrS Registry. Circulation. Genomic and Precision Medicine
Lin IY, Chiou YS, Wu LC, et al. (2019) CCM111 prevents hepatic fibrosis via cooperative inhibition of TGF-β, Wnt and STAT3 signaling pathways. Journal of Food and Drug Analysis. 27: 184-194
Sung YC, Liu YC, Chao PH, et al. (2018) Combined delivery of sorafenib and a MEK inhibitor using CXCR4-targeted nanoparticles reduces hepatic fibrosis and prevents tumor development. Theranostics. 8: 894-905
Chen Y, Liu YC, Sung YC, et al. (2017) Overcoming sorafenib evasion in hepatocellular carcinoma using CXCR4-targeted nanoparticles to co-deliver MEK-inhibitors. Scientific Reports. 7: 44123
Lin TT, Gao DY, Liu YC, et al. (2015) Development and characterization of sorafenib-loaded PLGA nanoparticles for the systemic treatment of liver fibrosis. Journal of Controlled Release : Official Journal of the Controlled Release Society
Liu JY, Chiang T, Liu CH, et al. (2015) Delivery of siRNA Using CXCR4-targeted Nanoparticles Modulates Tumor Microenvironment and Achieves a Potent Antitumor Response in Liver Cancer. Molecular Therapy : the Journal of the American Society of Gene Therapy
Gao DY, Lin TT, Sung YC, et al. (2015) CXCR4-targeted lipid-coated PLGA nanoparticles deliver sorafenib and overcome acquired drug resistance in liver cancer. Biomaterials. 67: 194-203
See more...